PX1 Research is the premier domestic supplier of research-grade Bronchogen (Ala-Glu-Asp-Leu / KEDW bioregulatory tetrapeptide) synthesized specifically for rigorous laboratory investigation. Designed for preclinical assays examining cellular responses to particulate matter, airborne toxicants, and industrial pollutants, our Bronchogen assays deliver verified chemical identity, ultra-low endotoxin thresholds, and documented lot-to-lot consistency.
PX1 Research is the premier domestic supplier of research-grade Bronchogen (Ala-Glu-Asp-Leu / KEDW bioregulatory tetrapeptide) synthesized specifically for rigorous laboratory investigation. Designed for preclinical assays examining cellular responses to particulate matter, airborne toxicants, and industrial pollutants, our Bronchogen assays deliver verified chemical identity, ultra-low endotoxin thresholds, and documented lot-to-lot consistency.
Identifying a reliable, high-quality Bronchogen environmental pollution supplier requires stringent quality verification, full analytical transparency, and pure synthetic integrity. PX1 Research supplies high-purity, laboratory-grade Bronchogen manufactured in domestic, GMP-compliant facilities to support advanced preclinical investigations into pulmonary toxicology, particulate matter exposure, and epithelial cell homeostasis.
Every batch of Bronchogen undergo rigorous third-party analytical testing, including High-Performance Liquid Chromatography (RP-HPLC) to confirm >98% purity and Mass Spectrometry (ESI-MS) to verify exact molecular identity. Research institutions depend on PX1 Research for fully documented, endotoxin-tested research compounds that ensure reproducible experimental conditions across cell culture, tissue explant, and animal models.
Bronchogen is a synthetic bioregulatory short peptide comprised of four amino acid residues (Lys-Glu-Asp-Trp or Ala-Glu-Asp-Leu depending on sequence nomenclature, historically designated as a short-chain bronchial regulatory sequence). As part of the broader class of short-chain signal peptides, its low molecular weight allows for efficient cellular uptake and targeted interaction with nuclear chromatin and cell-surface receptors in vitro.
In cell-free and cell-based structural assays, short-chain regulatory peptides interact directly with specific histone proteins and DNA promoter sequences. Research published in molecular biology literature suggests that these peptide-chromatin interactions can modulate transcriptomic expression patterns related to cellular stress response, mucociliary clearance, and structural protein synthesis within bronchial epithelial tissues.
To ensure precise physical properties during reconstituted assays, investigators must utilize pure, salt-controlled formulations. PX1 Research provides lyophilized Bronchogen prepared under strict climate and humidity controls, minimizing TFA (trifluoroacetic acid) counter-ion retention and preventing premature peptide aggregation prior to solubilization.
Environmental pollution models frequently utilize fine particulate matter (PM2.5), diesel exhaust particles (DEP), heavy metal dusts, and industrial oxidants to induce cellular stress in pulmonary models. In vitro data indicate that exposure to these toxic agents elevates intracellular reactive oxygen species (ROS), triggers pro-inflammatory cytokine cascades (such as IL-6, IL-8, and TNF-alpha), and disrupts tight junction integrity in bronchial epithelial monolayers.
Preclinical studies evaluating short-chain regulatory peptides in pollution-challenge models demonstrate several distinct cellular responses. When exposed to chemical irritants or airborne toxicants, cultured primary bronchial epithelial cells treated with Bronchogen exhibit altered expression profiles of protective heat-shock proteins (HSPs) and endogenous antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx).
Furthermore, animal models investigating industrial pollutant inhalation report that administration of bioregulatory tetrapeptides attenuates tissue remodeling, reduces goblet cell hyperplasia, and preserves alveolar architecture. These preclinical observations position Bronchogen as a primary candidate compound for investigating cytoprotective mechanisms against environmental and occupational respiratory hazards.
Maintaining epithelial barrier function is critical in cellular toxicology research. Environmental pollutants damage trans-epithelial electrical resistance (TEER) by downregulating key junctional proteins such as zonula occludens-1 (ZO-1), occludin, and claudin family members. In vitro assays demonstrate that Bronchogen treatment helps maintain TEER values in epithelial cultures subjected to toxic chemical challenges.
At the genetic level, short-chain regulatory peptides appear to act via epigenomic signaling pathways. Nuclear translocation studies indicate that small peptide sequences penetrate cellular and nuclear membranes to interact with specific DNA motifs. Preclinical assays suggest this binding alters the methylation status of regulatory gene regions, effectively promoting transcription of genes associated with cellular repair while downregulating pro-apoptotic signaling pathways.
Researchers analyzing transcriptomic profiles in air-liquid interface (ALI) airway models utilize high-purity Bronchogen to map the specific gene networks involved in repairing damaged bronchial mucosa following severe oxidant exposure.
For empirical integrity in toxicology and environmental research, sourcing reagents from a verified supplier is essential. Substandard peptide preparations containing synthesis side-products, uncoupled amino acids, or excess organic solvents introduce confounding variables that compromise preclinical experimental outcome data.
PX1 Research enforces strict quality control standards for every lot of Bronchogen. Each order includes a comprehensive, lot-specific Certificate of Analysis (COA) generated by an independent, ISO 17025-accredited laboratory. Analytical verification includes:
• Reverse-Phase HPLC (RP-HPLC): Confirms peptide chemical purity profile exceeds 98.0%, ensuring the absence of truncated deletion sequences. • Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact monoisotopic molecular weight matching theoretical structural calculations. • Endotoxin Quantification: Ensures bacterial endotoxin content remains strictly below 0.5 EU/mg via Chromogenic LAL assay. • Residual Solvent Analysis: Validates total removal of synthesis solvents including DMF, acetonitrile, and excess TFA counter-ions.
Endotoxin contamination is a major source of experimental bias in immunological, inflammatory, and toxicological assays. Lipopolysaccharides (LPS) present in poorly purified peptide preparations activate Toll-like receptor 4 (TLR4) pathways, causing false-positive inflammatory readouts that obscure the true biological effect of the research compound.
Because environmental pollution research frequently measures cytokine releases (e.g., IL-1beta, IL-6, TNF-alpha) identical to those triggered by LPS, absolute endotoxin control is paramount. PX1 Research subjects all lot batches to rigorous LAL testing, supplying guaranteed low-endotoxin research compounds suitable for sensitive primary cell cultures, organoid air-liquid interface systems, and in vivo animal models.
Explore our broader catalog of short-chain bioregulatory peptides to review technical specifications and analytical standards across our complete research peptide catalog.
In preclinical respiratory and tissue regeneration studies, researchers frequently compare or combine Bronchogen with other targeted peptide sequences to evaluate synergistic cytoprotective mechanism profiles. Understanding the comparative structural and functional differences between these compounds allows laboratories to design optimal experimental protocols.
For instance, while Bronchogen specifically modulates gene expression and antioxidant defenses in bronchial epithelial cells, the tripeptide KPV operates predominantly through anti-inflammatory signaling by inhibiting NF-kB nuclear translocation. Similarly, the bioregulatory tetrapeptide Vilon exhibits systemic chromatin-modulating and immune-system regulating activity in preclinical models.
In tissue destruction and wound-healing models following severe environmental chemical insult, investigators also benchmark Bronchogen against BPC-157, a synthetic gastric peptide known for modulating focal adhesion kinases and growth factor expression, as well as bioregulatory compounds like Epitalon. To browse our complete selection of analytical-grade sequences for comparative studies, visit our comprehensive catalog of research peptides.
Achieving reproducible experimental results requires standardized reconstitution and handling protocols within the laboratory environment. Bronchogen is supplied as a sterile, lyophilized cake that must be reconstituted using proper aseptic techniques under a laminar flow hood.
For aqueous cell culture applications, lyophilized Bronchogen should be reconstituted using sterile Bacteriostatic Water, Sterile Water for Injection (WFI), or phosphate-buffered saline (PBS, pH 7.4). Solubilization occurs rapidly upon gentle swirling; vortexing should be minimized to avoid mechanical shear stress or foam formation.
Once dissolved, working solution stock concentrations (typically 1 mg/mL or 10 mM) should be divided into single-use micro-aliquots using sterile polypropylene tubes to prevent repeated freeze-thaw cycles, which can induce molecular degradation over time. Detailed technical protocols and buffer compatibility data can be referenced within the PX1 Research library.
Lyophilized Bronchogen demonstrates high thermal stability when stored under recommended environmental conditions. Unreconstituted vials should be stored at -20°C for long-term storage (up to 24 months) or -80°C for extended archival preservation, protected from light and moisture desiccation.
Reconstituted liquid aliquots remain stable at 2°C to 8°C for up to 7 to 14 days, depending on buffer selection and pH. For long-term storage of reconstituted solutions, aliquots must be maintained at -80°C. PX1 Research packages all orders in temperature-controlled, insulated shipping containers with fast domestic fulfillment originating directly from our CA and AZ logistics hubs to preserve peptide integrity upon arrival.
Academic institutions, CROs, and biotechnology firms requiring consistent batch volumes for long-term toxicity studies can access dedicated supply channels through PX1 Research. We provide bulk quantity pricing, reserved single-lot production runs to eliminate inter-batch variance, and customized analytical reporting to meet institutional compliance standard specifications.
To discuss bulk procurement, custom analytical testing, or establish an institutional account, research teams are encouraged to apply directly through our wholesale lab account portal.
What is Bronchogen used for in laboratory research?
Bronchogen is supplied strictly as a research-grade bioregulatory tetrapeptide for in vitro and preclinical laboratory investigation. It is primarily studied in cellular toxicology models to evaluate its effects on bronchial epithelial cells exposed to environmental pollutants, particulate matter (PM2.5), and oxidative stressors.
How does PX1 Research verify Bronchogen purity and quality?
Every lot of Bronchogen from PX1 Research undergoes independent third-party testing via RP-HPLC (verifying >98% purity) and ESI-Mass Spectrometry (verifying molecular weight identity). Each shipment includes a lot-specific Certificate of Analysis (COA).
What are the endotoxin limits for PX1 Research Bronchogen?
PX1 Research enforces strict endotoxin controls, guaranteeing that Bronchogen contains less than 0.5 EU/mg as measured by Chromogenic LAL testing, ensuring suitability for sensitive cell culture and animal models.
How should lyophilized Bronchogen be stored upon delivery?
Lyophilized Bronchogen vials should be stored at -20°C or -80°C in a dry, dark environment. Stored under these conditions, the unhydrated powder maintains stability for up to 24 months.
What solvents are recommended for reconstituting Bronchogen for in vitro assays?
Bronchogen reconstitutes readily in sterile Bacteriostatic Water, Sterile Water for Injection (WFI), or sterile PBS (pH 7.4). Aseptic techniques should be used under a laminar flow hood during handling.
Where does PX1 Research ship Bronchogen orders from?
All PX1 Research compounds are manufactured in domestic US facilities and shipped directly from our primary fulfillment centers located in California and Arizona, offering fast same-day dispatch Monday through Friday.
Can institutions purchase bulk lots of Bronchogen for long-term studies?
Yes. Institutional buyers and laboratories can request bulk orders and single-lot reservations to ensure uniform batch characteristics across multi-phase experimental studies via our wholesale program.
Is Bronchogen approved for human consumption or therapeutic use?
No. Bronchogen provided by PX1 Research is strictly for laboratory research use only. It is not intended for human or animal therapeutic, diagnostic, cosmetic, or clinical administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.